ASCO/CAP 2018 breast cancer HER2 testing guidelines: summary of pertinent recommendations for practice in Australia

Abstract

The latest update to the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP)HER2 testing in breast cancer guidelines was published in 2018. A multidisciplinary expert committee, convened under the auspices of the Royal College of Pathologists of Australasia (RCPA)Structured Pathology Reporting framework, evaluated the implications of these guidelines for clinical practice in Australia. Following feedback from professional bodies, including the RCPA and CanSAC, peer review was invited. The final document prepared by the authors, endorsed by the Expert Committee RCPA Structured Pathology Reporting of Breast Cancer and by CanSAC, is published herein.